Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.

Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB.

Dig Dis Sci. 2010 May;55(5):1396-405. doi: 10.1007/s10620-009-0839-8. Epub 2009 Jun 9.

2.

Ipilimumab-induced toxicities and the gastroenterologist.

Cheng R, Cooper A, Kench J, Watson G, Bye W, McNeil C, Shackel N.

J Gastroenterol Hepatol. 2015 Apr;30(4):657-66. doi: 10.1111/jgh.12888. Review.

PMID:
25641691
3.

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.

Lens M, Ferrucci PF, Testori A.

Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):105-13. Review.

PMID:
18537753
4.

Ipilimumab.

[No authors listed]

Drugs R D. 2010;10(2):97-110. doi: 10.2165/11584510-000000000-00000. Review.

5.

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.

Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P.

Oncogene. 2015 Oct;34(43):5411-7. doi: 10.1038/onc.2015.5. Epub 2015 Feb 9. Review.

Supplemental Content

Support Center